Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Part 1 and 2:~* Healthy adult male and female subjects between the ages of 21-55 years inclusive.~* Subject must be willing to remain in the Clinical Research Unit (CRU) for a minimum of 72 hours after each dose.~Part 3:~* RA male and female subjects between the ages of 21-70 years inclusive~* Evidence of active RA disease~* Inadequate response to biologic or non-biologic DMARDs~* Subjects will be required to be on background therapy with methotrexate.~Exclusion Criteria:~Parts 1, 2 and 3:~* BMI \<18 or \>32 kg/m2~* Clinically significant findings in physical exams and laboratory tests at screening and/or baseline~* Unwilling to abstain from alcohol for 48 hours prior to study start, during CRU confinement, as applicable, and for 48 hours prior to study visits.~* Unwilling to abstain from exercise more strenuous than walking during CRU confinement, as applicable, and for 48 hours prior to study visits.~Parts 1 and 2:~* Use of any prescription, non-prescription, or herbal medications as well as supplements or vitamins within 4 weeks prior to dosing, unless approved by the Investigator.~* Smoking more than 10 cigarettes, or the equivalent, per day.~Part 3:~* Current or previous history of inflammatory joint disease other than RA~* Evidence of extra-articular RA disease or systemic involvement~* Currently taking any medications other than those allowed per protocol guidelines~* Any surgical procedure including bone or joint surgery within 12 weeks prior to dosing~* Use of intra-articular (IA), intramuscular (IM), or IV corticosteroids for RA~* Neuropathies and neurovasculopathies~* Concomitant use of statins while on study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 1-FPA008/Placebo Randomize DoseLevels1-4 (Type: EXPERIMENTAL): Single infusion at 4 different dose levels
- 2-FPA008/Placebo Randomize DoseLevels1-2 (Type: EXPERIMENTAL): Dual Infusions at 2 different dose levels
- 3-FPA008 Open-Label DoseLevels 1-3 (Type: EXPERIMENTAL): Dual infusions at 1 dose level AND Dual/Triple infusions at 2 different dose levels

Based on this trial design, predict the completion outcome and termination type (if applicable).